The Institute for Immunologic Intervention at the CDI investigates T cell development in the thymus and T cell immune responses in peripheral tissues.
3i’s Mission
The Hackensack Meridian Health (HMH) Center for Discovery and Innovation (CDI) established the Institute for Immunologic Intervention (3i) with the goal of advancing research in immunology to combat infections, cancer, and inflammatory diseases by enhancing the human immune system's responses. Comprising a team of expert scientists, including basic researchers, physician-scientists, and clinicians, the 3i focuses on understanding fundamental mechanisms of infectious immunity, tumor immunity, alloimmunity, and autoimmunity in clinical contexts. In close clinical and translational research partnerships with the HMH John Theurer Cancer Center and the Georgetown Lombardi Comprehensive Cancer Center (LCCC), which collectively form one of the national NCI-designated comprehensive cancer centers the 3i aims to apply this knowledge to improve cancer immunotherapy, interventions for autoimmune and alloimmune conditions, and infection prevention. The scientists at 3i cover diverse fields such as cancer immunology, immunotherapy, T cell biology, genetics, and microbiome influence on antitumor immunosurveillance.
Physician scientists at Hackensack Meridian Health
Steven A Lee-Kong, M.D.
Colon and Rectal Surgery
Howard M Ross, M.D.
Colon and Rectal Surgery
Martin E Gutierrez, M.D.
GI and Thoracic Medical Oncology
David Siegel, M.D.
Multiple Myeloma, AL Amyloidosis
Lombardi Comprehensive Cancer Center - Based Faculty Members
Samir Khleif, M.D.
Translational Tumor Immunology
Louis Weiner, M.D.
Medical Oncology, Gastrointestinal Cancers
Michael Atkins, M.D.
Anti-angiogenic Therapy, Hematology, Immunotherapy, Kidney Cancer
Alejandro Villagra, Ph.D.
Tumor Microenvironment, Epigenetics, Tumor Immunology
Ben Weinberg, M.D.
Gastrointestinal Medical Oncology, Hematology Oncology
Joyce Slingerland, M.D., Ph.D.
Cancer Host Interactions, Breast Cancer